Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Clinical Trials
100%
Natural History
100%
Age-related Macular Degeneration
100%
Visual Acuity
100%
Occult
100%
Photodynamic Therapy
40%
Fluorescein Angiography
40%
Coefficient of Determination
40%
Meta-analysis
20%
Strong Correlation
20%
Inhibition Studies
20%
Visual Loss
20%
Subfoveal
20%
Neovascularization
20%
Financial Disclosure
20%
Major Determinants
20%
Myopic Choroidal Neovascularization (mCNV)
20%
Vision Loss
20%
Acetate
20%
Exudative
20%
Angiographic Classification
20%
Macular Photocoagulation
20%
Ranibizumab
20%
Verteporfin
20%
Neovascular Age-related Macular Degeneration (nAMD)
20%
Marina
20%
Anti-VEGF Antibody
20%
Horizontal Translation
20%
Translation Initiation Factor
20%
Ocular Neovascularization
20%
VEGF Inhibition
20%
Medicine and Dentistry
Clinical Trial
100%
Age Related Macular Degeneration
100%
Visual Acuity
100%
Visual Impairment
40%
Photochemotherapy
40%
Fluorescein Angiography
40%
Diseases
20%
Meta-Analysis
20%
Vasculotropin
20%
Choroidal Neovascularization
20%
Laser Coagulation
20%
Verteporfin
20%
Ranibizumab
20%
Wet Macular Degeneration
20%
Vasculotropin Antibody
20%
Anecortave
20%
Neuroscience
Age-Related Macular Degeneration
100%
Visual Acuity
100%
Angiography
40%
Fluorescein
40%
Behavior (Neuroscience)
20%
Vascular Endothelial Growth Factor
20%
Choroidal Neovascularization
20%
Ranibizumab
20%
Meta-Analysis
20%
Verteporfin
20%
Vasculotropin Antibody
20%
Anecortave
20%
Biochemistry, Genetics and Molecular Biology
Clinical Trial
100%
Visual Acuity
100%
Vascular Endothelial Growth Factor
40%
Photodynamics
40%
Fluorescein
40%
Neovascularization (Pathology)
40%
Subretinal Neovascularization
20%
Anecortave
20%
Ranibizumab
20%